Hirsch Andrew has filed 21 insider transactions across 2 companies since June 2023.
Most recent transaction: a grant/award of 700000 shares of C4 Therapeutics, Inc. ($CCCC) on February 13, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | A | Common Stock | 700000 | $0.00 | 1,123,145.0000 | 96,914,418 | 165.43% | 0.72% |
| Feb. 15, 2026 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 9057 | $1.89 | 1,074,934.0000 | 96,914,418 | 0.84% | 0.01% |
| Feb. 15, 2026 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | M | Common Stock | 20400 | $0.00 | 1,083,991.0000 | 96,914,418 | 1.92% | 0.02% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 39154 | $1.89 | 1,083,991.0000 | 96,914,418 | 3.49% | 0.04% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | M | Common Stock | 81725 | $0.00 | 1,123,145.0000 | 96,914,418 | 7.85% | 0.08% |
| June 6, 2025 | Editas Medicine, Inc. | $EDIT | Hirsch Andrew | Director | A | Stock Option (right to buy) | 37500 | $0.00 | 37,500.0000 | 82,976,284 | 9999.99% | 0.05% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | A | Stock Option (Right to Buy) | 335300 | $0.00 | 335,300.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | A | Common Stock | 223500 | $0.00 | 445,362.0000 | 0 | 100.74% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 12847 | $3.18 | 432,515.0000 | 0 | 2.88% | 0.00% |
| Feb. 15, 2025 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 9370 | $3.18 | 423,145.0000 | 0 | 2.17% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | M | Common Stock | 12500 | $0.00 | 227,412.0000 | 0 | 5.82% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 5550 | $6.04 | 221,862.0000 | 0 | 2.44% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | M | Performance Restricted Stock Units | 12500 | $0.00 | 35,000.0000 | 0 | 26.32% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 3329 | $6.36 | 214,912.0000 | 0 | 1.53% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | M | Performance Restricted Stock Units | 7500 | $0.00 | 47,500.0000 | 0 | 13.64% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | M | Common Stock | 7500 | $0.00 | 218,241.0000 | 0 | 3.56% | 0.00% |
| May 30, 2024 | Editas Medicine, Inc. | $EDIT | Hirsch Andrew | Director | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | A | Stock Option (Right to Buy) | 465500 | $0.00 | 465,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | A | Common Stock | 103400 | $0.00 | 217,301.0000 | 0 | 90.78% | 0.00% |
| Feb. 15, 2024 | C4 Therapeutics, Inc. | $CCCC | Hirsch Andrew | President & CEO | F | Common Stock | 6560 | $7.90 | 210,741.0000 | 0 | 3.02% | 0.00% |
| June 1, 2023 | Editas Medicine, Inc. | $EDIT | Hirsch Andrew | Not found | A | Stock Option (right to buy) | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |